From SBA-financed asset purchases to DSO equity recaps, this guide breaks down the deal structures that close podiatry practice transactions at fair value for both physicians and buyers.
Acquiring or selling a podiatry practice requires deal structures that account for the unique risks of physician-dependent revenue, complex healthcare compliance rules, and payer mix dynamics. Unlike traditional business acquisitions, podiatry deals must address the likelihood that a significant portion of practice revenue walks out the door with the selling physician, making earnouts, employment agreements, and seller equity rollovers critical tools. Most podiatry practice transactions in the $1M–$5M revenue range use an asset purchase structure, which allows the buyer to avoid assuming unknown liabilities and provides favorable tax treatment through stepped-up asset basis. Financing is commonly layered across SBA 7(a) loans, seller notes, and buyer equity injections. For practices being absorbed into PE-backed platforms or DSO roll-ups, partial equity recapitalizations offer sellers liquidity today while preserving upside in the aggregated entity. Understanding which structure fits your situation — whether you're a solo podiatrist buying your first practice, a search fund operator, or a retiring DPM looking to maximize exit proceeds — is the foundation of a successful transaction.
Find Podiatry Practice Businesses For SaleAsset Purchase with Seller Earnout
The buyer purchases the practice's assets — including patient records, equipment, lease, and goodwill — rather than the legal entity. A portion of the purchase price is deferred and paid to the seller only if specified revenue or patient retention thresholds are met over a 12–24 month period post-close. This is the most common structure for podiatry acquisitions where the selling physician is the primary revenue driver.
Pros
Cons
Best for: Individual podiatrist buyers or search fund operators acquiring a practice where the selling physician represents more than 60% of total clinical production and plans to transition out within 12–18 months.
SBA 7(a) Financed Asset Purchase
The buyer secures an SBA 7(a) loan — up to $5 million — to finance the majority of the purchase price, with a required buyer equity injection of 10–15% and an optional seller note of 5–10% on full standby during the SBA loan term. The seller receives the bulk of proceeds at close, providing clean liquidity for a retiring DPM. This is the most accessible financing path for individual physician buyers without institutional capital.
Pros
Cons
Best for: Individual podiatrists transitioning from associate or employed roles to practice ownership, particularly when acquiring a practice with 3+ years of clean financials and EBITDA margins of 20% or better.
Partial Equity Recapitalization
Rather than a full sale, the practice owner sells a majority stake — typically 51–80% — to a private equity-backed specialty practice management group or DSO platform, retaining 20–49% ownership. The selling physician receives a significant liquidity event at close and continues practicing under the platform's management infrastructure, with potential for a second liquidity event when the platform itself is sold or recapitalized in 3–7 years.
Pros
Cons
Best for: Established podiatrists aged 50–65 with a high-performing practice generating $2M–$5M in annual collections who want liquidity now but are not yet ready to retire and see value in participating in a platform's future growth.
Retiring Solo Podiatrist — SBA 7(a) Full Buyout
$1,800,000
SBA 7(a) loan: $1,440,000 (80%); buyer equity injection: $180,000 (10%); seller note on full standby: $180,000 (10%)
Practice collects $1.4M annually with 22% EBITDA margin. Seller is a 62-year-old DPM with no associates, agreeing to a 12-month paid transition at $180,000 per year. Seller note at 6% interest, 10-year term, on full standby during SBA loan period. Asset purchase with goodwill, patient records, equipment, and lease assignment. Earnout waived given seller's 12-month clinical commitment.
Two-Physician Group Practice — Asset Purchase with Earnout
$3,200,000
SBA 7(a) loan: $2,240,000 (70%); buyer equity: $480,000 (15%); seller note: $320,000 (10%); earnout: $160,000 (5%) tied to 24-month collections retention
Practice generates $2.8M in annual collections across two DPMs; selling physician accounts for 65% of production. Earnout of $160,000 paid in two equal tranches at 12 and 24 months post-close, contingent on total practice collections remaining above $2.5M in year one and $2.6M in year two. Seller employment agreement for 24 months at $220,000 annually. Associate physician retained with updated employment agreement and non-solicitation clause.
High-Volume Diabetic Wound Care Practice — DSO Equity Recapitalization
$5,500,000 implied enterprise value
PE platform acquires 70% stake for $3,850,000 cash to seller; seller retains 30% equity rollover valued at $1,650,000
Practice generates $4.2M in annual collections with 28% EBITDA margin; strong diabetic wound care and orthotics revenue. Seller receives $3.85M cash at close, retains 30% equity in the platform's operating entity. Seller continues as lead clinician under a 3-year employment agreement at $350,000 base salary plus clinical productivity bonus. Platform assumes billing, HR, and compliance infrastructure. Second liquidity event targeted at platform sale in 4–6 years, with seller's retained equity expected to appreciate 2–3x based on platform EBITDA expansion.
Find Podiatry Practice Businesses For Sale
Pre-screened targets ready for your deal structure — free to join.
The asset purchase financed through an SBA 7(a) loan is the most common structure for podiatry practice acquisitions in the $1M–$5M revenue range. The buyer acquires the practice's goodwill, patient records, equipment, and lease — but not the legal entity — which limits exposure to legacy liabilities. SBA financing covers 75–85% of the purchase price, with the buyer contributing 10–15% in equity and the seller often carrying a note for 5–10%. When the selling physician is the primary revenue driver, an earnout component tied to patient retention is layered on top to align incentives during the ownership transition.
An earnout defers a portion of the purchase price — typically 15–25% — and pays it to the seller only if specific performance targets are met after closing. In podiatry deals, earnouts are most commonly tied to total practice collections over 12–24 months post-close. For example, if the selling DPM commits to a 18-month clinical transition and the practice maintains 90% of prior-year collections, the seller receives the full earnout. If collections fall short, the earnout is reduced proportionally. The key to a workable earnout is precise contractual language defining the metric, the measurement period, and which party bears responsibility for events outside the seller's control — such as payer credentialing delays initiated by the buyer.
It depends on the state. Many states have corporate practice of medicine (CPOM) laws that restrict non-physician entities from owning a medical practice outright. In CPOM states, non-physician buyers — including PE-backed platforms and DSO operators — typically use a Management Services Organization (MSO) structure, where a physician-owned professional corporation (PC) holds the clinical license and provider contracts while the MSO entity owns the practice's non-clinical assets and receives management fees. Buyers should engage a healthcare M&A attorney familiar with podiatry-specific CPOM rules in the target state before structuring any transaction.
Podiatry practices are most commonly valued using a multiple of EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), with owner compensation addbacks applied to normalize the financials. For established practices with $1M–$5M in annual collections and 15–30% EBITDA margins, transaction multiples typically range from 3x to 5.5x adjusted EBITDA. Value is higher for practices with multiple providers, diversified payer mix, clean billing history, and recurring chronic care revenue from diabetic patients and orthotics programs. Practices heavily dependent on a single physician or with Medicaid concentration above 30% typically trade at the lower end of the range.
A seller note is a form of deferred payment where the buyer owes the seller a portion of the purchase price over time, typically at a fixed interest rate of 5–8%. In SBA-financed podiatry deals, the seller note is usually 5–10% of the purchase price and is placed on 'full standby,' meaning no payments are made to the seller during the SBA loan term. Buyers request seller notes because they signal confidence — a seller willing to leave money in the deal is indicating they believe the practice will perform. For SBA lenders, seller participation is a positive underwriting signal that can accelerate loan approval.
Patient attrition is the primary valuation risk in any podiatry practice acquisition, which is why earnouts and transition employment agreements are standard deal features. To mitigate attrition, buyers should require the selling physician to remain clinically active for 12–24 months post-close and participate in patient introduction communications. Practices with documented diabetic care protocols, active recall systems, and a roster of referral-generating relationships with primary care physicians or endocrinologists tend to retain patients better than those built entirely on the personal reputation of the selling DPM. The presence of an associate podiatrist who already sees a portion of the patient base is the single most effective structural protection against post-sale patient attrition.
More Podiatry Practice Guides
More Deal Structure Guides
Find the right target, structure the deal, and close with confidence.
Create your free accountNo credit card required
For Buyers
For Sellers